海思科：获得创新药HSK44459片新增适应症《药物临床试验批准通知书》

Core Viewpoint - The company, Haishi Ke (002653.SZ), has received approval from the National Medical Products Administration for clinical trials of HSK44459 tablets, a new drug for treating inflammatory bowel diseases, including ulcerative colitis and Crohn's disease [1] Group 1: Drug Development - HSK44459 tablets are independently developed by the company and possess independent intellectual property rights [1] - The drug has shown clear targets, definite efficacy, and good safety in preclinical studies, indicating high development potential as a small molecule drug [1] - The drug is expected to address the current shortage of effective treatments for inflammatory bowel diseases, offering a favorable benefit/risk ratio for clinical applications [1]